

REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours

C. Lévy¹, D. Allouache¹, J. Lacroix^{2,3}, A. E. Dugué⁴, S. Supiot⁵, M. Campone⁵, M. Mahe⁶, S. Kichou², M. Leheurteur⁷, C. Hanzen⁸, V. Dieras⁹, Y. Kirova¹⁰, F. Campana¹⁰, E. Le Rhun¹¹, L. Gras¹², T. Bachelot¹³, M.-P. Sunyach¹⁴, I. Hrab¹, J. Geffrelot¹⁵, K. Gunzer^{1,4}, J.-M. Constans^{3,16}, J.-M. Grellard⁴, B. Clarisse⁴ & X. Paoletti¹⁷

Departments of ¹Oncology; ²Radiology, Centre François Baclesse, Caen; ³GIP Cyceron, Caen; ⁴Department of Clinical Research, Centre François Baclesse, Caen; Departments of ⁵Oncology; ⁶Radiotherapy, Institut de Cancérologie de l'Ouest René Gauducheau, Nantes-Saint Herblain, Caen; Departments of ⁷Oncology; ⁸Radiotherapy, Centre Henri Becquerel, Rouen; Departments of ⁹Oncology; ¹⁰Radiotherapy, Institut Curie, Paris; Departments of ¹¹Oncology; ¹²Radiotherapy, Centre Oscar Lambret, Lille; Departments of ¹³Oncology; ¹⁴Radiotherapy, Centre Léon Bérard, Lyon; ¹⁵Department of Radiotherapy, Centre François Baclesse, Caen; ¹⁶Department of Radiology, Centre Hospitalier Universitaire, Caen; ¹⁷Department of Biostatistics, Institut Curie/Inserm U900, Paris, France

Ann Oncol 2015; 25: 611–618 (doi: 10.1093/annonc/mdu465)

In the original manuscript, there was an error in the formatting of Table 2.

The corrected table is below.

Table 2. Adverse events considered by the investigator to be related to treatment, except alopecia (N = 19)^a

| No. of patients | Dose level 0 (N = 3) | | Dose level 1 (N = 4) | | Dose level 2 (N = 3) | | Dose level 3 (N = 9) | | Total no. of patients |
|-------------------------------|----------------------|---------|----------------------|---------|----------------------|---------|----------------------|---------|-----------------------|
| | Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 1 | Grade 2 | |
| In-field side-effects | | | | | | | | | |
| Headache | | | | | | | 1 | | 1 |
| Nausea | | | 1 | | | | 2 | 1 | 4 |
| Vomiting | 1 | | | | | | | 1 | 2 |
| No. of patients | | 1 | | 1 | | 0 | | 3 | 5 |
| Out-field side-effects | | | | | | | | | |
| Arterial hypertension | | | | | 1 | | | 3 | 4 |
| Asthenia | | | | 1 | | | 1 | 1 | 3 |
| Pain | | | | | | | 1 | | 1 |
| Abdominal pain | | | | | | | | 1 | 1 |
| Lymphopenia | | | | | | | | 1 | 1 |
| Skin/mucus disorders | | | | | | | | 1 | 1 |
| Appetite loss | 1 | | | | | | | | 1 |
| No. of patients | | 1 | | 1 | | 1 | | 6 | 9 |
| Total no. of patients | | 1 | | 1 | | 1 | | 8 | 11 |

^aAdverse events considered not related to treatment were: grade 3 asthenia and grade 3 hyperglycaemia in 1 patient; grade 2 AEs in 13 patients [asthenia (n = 4), pain (n = 4), infection (n = 4), headache (n = 3), balance disorder (n = 3), constipation (n = 2), insomnia (n = 2), anorexia (n = 1), hyperglycaemia (n = 1), hyponatremia (n = 1), paraesthesia (n = 1), cutaneous/mucus disorder (n = 1), liver disorder (n = 1), ocular disorder (n = 1), epigastralgia (n = 1)].